Product Images Levetiracetam

This appears to be a figure showing the Responder Rate (>50% Reduction From Baseline) for Study 1. It shows the percentages of responders for the Placebo group (N=95) and the Levetiracetam groups taking 1000 mg/day (N=37) and 3000 mg/day (N=101). There is also a note indicating that one of the groups had a statistically significant difference from the placebo group.*

The text provides a figure, labeled as Figure 2, which shows the Responder Rate (>50% Reduction From Baseline) in Study 2, specifically in Period A. There are percentages ranging from 0% to 40% on the y-axis, and two groups identified on the x-axis, Placebo and Levetiracetam, which had different dosages (1000 moj/day and 2000 moj/day) and number of participants in each group (N=111, N=106, N=105). The text also indicates that there were statistically significant results for Levetiracetam versus placebo.*

The figure is showing the Responder Rate (>50% Reduction From Baseline) in Study 3 for two drugs, Placebo and Levetiracetam. Levetiracetam is given at a dose of 3000 mg/day (N=180) and Placebo at N=104. The Responder Rate is shown on the Y-axis ranging from 0% to 45%. The X-axis has the percentages ranging from 0% to 50%, in increments of 5% and the two drugs are on the X-axis. The statistical significance of Levetiracetam versus Placebo is also mentioned in the footnote.*

The graph in Figure 4 of the study shows the responder rate (2509 reduction from baseline) in two groups of patients receiving placebo or Levetiracetam. Levetiracetam showed a statistically significant difference compared to the placebo group. The vertical axis represents the percentage of patients, while the horizontal axis represents different response rates.*

ot-available*

The figure 6 shows the responder rate for a 50% reduction from the baseline in PGTC seizures frequency per week for study 7. The placebo (N=84) and Levetiracetam groups were compared, where Levetiracetam group had a statistically significant difference compared to placebo (P < 0.05). The responder rate for Levetiracetam group was 72.2% compared to 45.2% for placebo.*

Dipense na gt igh reitantcoianer R only. This is a medication expressed in milligrams of levetiracetam. Store between 20-25°C (68-77°F) unless permitted to be kept between 15-30°C (53-86°F). It is manufactured by Zhejang Hushai Pharmaceutical Co. Ltd in China and distributed by Soiotethowe US LLC in Somerset, NJ 06473, USA. This information provides a brief description of the medication, its format, and guidelines on appropriate storing.*

This is a medicine labeling text for Levetiracetam Tablets, USP. It contains information such as the recommended storage conditions, dosage instructions, and the manufacturer's details. The tablets are contained in a child-resistant and airtight container and should be stored at a temperature between 15-30°C. The medication should be dispensed along with a medication guide to each patient. The text also provides details of the manufacturer and the composition of the drug. There is a note about an uncoated area on the box.*

This is a description of a medication bottle containing Levetiracetam tablets. The container is child-resistant and tamper-resistant. Each tablet contains 1000 mg of the medication. The packaging includes information on dosage. The medication should be stored at a temperature between 15-30°C (53-86°F). The manufacturer is S Zbejong Huahai Pharmaceutical Co. Ltd in China, and it is distributed by Soco Healthcare US, LLC in New Jersey. The product comes with a medication guide.*